• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Aaron Lyss on What the Next Oncology Payment Model Should Include

Video

Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.

Transcript:

What would you like to see in the next iteration of a payment model for oncology?

I think there are 4 parameters that are critical to alternative payment models in oncology. The first is benchmarking. Are the performance benchmarks associated with the model achievable and reasonable for the practices who are participating? I think the second important issue is control and accountability. By that,I mean, does a practice, do providers have control over the outcomes of the model? Can they then be held accountable for their performance? Then I think the third issue is what I'll refer to as bilateralism. That's basically, is the payment structure of the model suitable both to the provider group as well as to the payer, based on the value that the practice can create in the model? Then the fourth issue is scalability. Does the model apply to a broad enough population of patients that enables the practice to focus on all the improvements in care delivery that they want to see across a very broad population? Then from the payer perspective, does the model work for a broad enough population of practices that it can apply to a nationwide cohort of practices who would be participating?

Related Videos
Joshua K. Sabari, MD
Nicoletta Colombo, MD, PhD
Khush Kharidia, MD
Jo Varshney, PhD, DVM, CEO and founder, VeriSIM Life
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Harry Travis, BS Pharm, MBA, president at The Travis Group, LLC
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Chelsea Renfro, PharmD, research and engagement pharmacist, Vanderbilt Specialty Pharmacy
Marc S. Raab, MD, PhD, University Hospital Heidelberg
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.